Adalimumab was the most frequently (40.9%) used TNFα inhibitor for the total study population, but etanercept was the most used TNFα inhibitor in RD patients (47.5%), infliximab in IBD patients (62.4%). The gene discussed is TNF; the disease is inflammatory bowel disease.